The Medical University of South Carolina
Welcome,         Profile    Billing    Logout  
 29 Trials 
64 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Sleckman, Bethany G
SUNRAY-01, NCT06119581: A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

Recruiting
3
1016
Europe, Canada, Japan, US, RoW
LY3537982, Olomorasib, Pembrolizumab, Placebo, Cisplatin, Carboplatin, Pemetrexed
Eli Lilly and Company, Loxo Oncology, Inc.
Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis
10/26
10/29
AZUR-2, NCT05855200: Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer

Recruiting
3
711
Europe, Canada, Japan, US, RoW
Dostarlimab, CAPEOX, FOLFOX
GlaxoSmithKline
Colonic Neoplasms, Neoplasms, Colon
12/28
12/30
NCT05234177: Tempus CRC Surveillance Study: a CtDNA Biomarker Profiling Study of Patients with CRC Using NGS Assays

Recruiting
N/A
160
US
Observation
Tempus AI
Colorectal Cancer
02/25
02/27
NCT05236114: GEMINI-NSCLC: NSCLC Biomarker Study

Recruiting
N/A
1200
US
Observation
Tempus AI, AstraZeneca
Non-Small Cell Lung Cancer
06/29
06/29
NCT01817192: Adjuvant Chemotherapy in Patients With Intermediate or High Risk Stage I or Stage IIA Non-squamous Non-Small Cell Lung Cancer

Active, not recruiting
N/A
420
Europe, US
Adjuvant Chemotherapy, Radiographic surveillance, 14-Gene Prognostic Assay
Razor Genomics, Encore Clinical
Non-Small Cell Lung Cancer
05/27
05/27
Milstone, Aaron
TETON, NCT04708782: Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis

Hourglass May 2024 - Aug 2024 : Topline data for IPF
Hourglass Jan 2023 - Mar 2023 : Enrollment completion of TETON trial for IPF
Recruiting
3
576
Canada, US
Placebo, Inhaled Treprostinil, Tyvaso, Treprostinil Ultrasonic Nebulizer
United Therapeutics
Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease
06/25
06/25
TETON-PPF, NCT05943535: Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis

Recruiting
3
698
Canada, US, RoW
Placebo, Inhaled Treprostinil, Tyvaso, Treprostinil Ultrasonic Nebulizer
United Therapeutics
Progressive Pulmonary Fibrosis, Interstitial Lung Disease
11/27
11/27
NCT05130970 / 2021-003162-12: Garadacimab Safety, Pharmacokinetics, and Pharmacodynamics in Idiopathic Pulmonary Fibrosis

Completed
2
81
Europe, Canada, US, RoW
Garadacimab, Factor XIIa antagonist monoclonal antibody, CSL312, Placebo
CSL Behring
Idiopathic Pulmonary Fibrosis
01/24
01/24
NCT05032066: A Multicenter Trial to Evaluate the Efficacy, Safety and Tolerability of HZN-825 in Subjects With Idiopathic Pulmonary Fibrosis

Jan 2024 - Dec 2024: Data from trial for diffuse cutaneous systemic sclerosis
Terminated
2
153
Europe, Canada, Japan, US, RoW
HZN-825, Placebo
Amgen
Idiopathic Pulmonary Fibrosis
07/24
01/25
NCT05671835: Study of TTI-101 in Participants With Idiopathic Pulmonary Fibrosis

Recruiting
2
75
US
TTI-101, Placebo
Tvardi Therapeutics, Incorporated
Idiopathic Pulmonary Fibrosis
03/25
07/25
Silvestri, Gerard A
ALTITUDE, NCT04171492: Nodify XL2 Classifier Clinical Utility Study in Low to Moderate Risk Lung Nodules

Recruiting
N/A
2000
Canada, US
Biodesix, Inc.
Nodule Solitary Pulmonary, Non-small Cell Carcinoma
12/25
12/26
Cook, Chad E
NCT06262880: Dietary Supplementation on Gastrointestinal Barrier Function

Recruiting
N/A
126
US
plant derived phenolics, Microcrystaline cellulose (MCC)
Brightseed
Intestinal Permeability
12/24
02/25
NCT06548048: Dietary Supplementation on Fat Oxidation

Recruiting
N/A
16
US
Dietary supplement containing plant derived phenolics, Microcrystaline cellulose
Brightseed
Overweight, Obesity
11/24
12/24
Smith, Sarah
NCT05671835: Study of TTI-101 in Participants With Idiopathic Pulmonary Fibrosis

Recruiting
2
75
US
TTI-101, Placebo
Tvardi Therapeutics, Incorporated
Idiopathic Pulmonary Fibrosis
03/25
07/25
BTCRC-LUN17-127, NCT03575793: A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients With Recurrent Small Cell Lung Cancer

Checkmark Initial data from trial in combination with opdivo and yervoy for recurrent small cell lung cancer at ASCO 2021
Jun 2021 - Jun 2021: Initial data from trial in combination with opdivo and yervoy for recurrent small cell lung cancer at ASCO 2021
Checkmark Data from combination with nivolumab and ipilimumab for 2L & 3L SCLC
May 2021 - May 2021: Data from combination with nivolumab and ipilimumab for 2L & 3L SCLC
Checkmark From trial in combination with nivolumab and plinabulin for recurrent SCLC at ASCO 2021
More
Completed
1/2
39
US
Nivolumab, Opdivo, Plinabulin, Ipilimumab, Yervoy
Salma Sabbour, BeyondSpring Pharmaceuticals Inc., Bristol-Myers Squibb, Rutgers Cancer Institute of New Jersey
Lung Cancer, SCLC
09/23
07/24
Lee, Lara Wine
NCT05070754: Cold Atmospheric Plasma Device for Pediatric Molluscum and Verruca

Completed
4
17
US
Floating electrode-dielectric barrier device (FE-DBD) cold atmospheric plasma (CAP), Non-thermal atmospheric pressure plasma (NTAP), Cryotherapy, Cold Therapy, Liquid Nitrogen, Canthardin Collodion, Cantharidin
Medical University of South Carolina, The Skin Center Dermatology Group
Verruca Vulgaris, Molluscum Contagiosum Skin Infection
12/22
12/22
NCT05372419: A Study of (LY3650150) Lebrikizumab to Assess the Safety and Efficacy of Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis and Skin of Color

Active, not recruiting
3
80
US
Lebrikizumab, LY3650150, DRM06
Eli Lilly and Company
Atopic Dermatitis
05/24
02/25
NCT05937672: Cold Atmospheric Plasma Device Extension Study

Recruiting
3
40
US
Floating electrode-dielectric barrier device (FE-DBD) cold atmospheric plasma (CAP), Non-thermal atmospheric pressure plasma (NTAP)
Medical University of South Carolina, The Skin Center Dermatology Group
Verruca Vulgaris, Molluscum Contagiosum
05/25
07/25
ADorable-1, NCT05559359: A Study of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis

Recruiting
3
360
Europe, Canada, Japan, US, RoW
Lebrikizumab, LY3650150, DRM06, Placebo, Topical Corticosteroid (TCS)
Eli Lilly and Company, Dermira, Inc.
Atopic Dermatitis, Eczema
02/26
02/27
BRAVE-AA-PEDS, NCT05723198: A Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata

Recruiting
3
595
Europe, Canada, Japan, US, RoW
Baricitinib, LY3009104, Placebo
Eli Lilly and Company
Areata Alopecia, Alopecia, Hypotrichosis, Hair Diseases, Skin Diseases, Pathological Conditions, Anatomical
09/24
08/29
ADorable-2, NCT05735483: A Study to Assess the Long-Term Safety and Efficacy of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis

Enrolling by invitation
3
310
Europe, Canada, Japan, US, RoW
Lebrikizumab, LY3650150, Placebo
Eli Lilly and Company
Atopic Dermatitis, Eczema
06/26
06/26
BRAVE-AA1, NCT03570749: A Study of Baricitinib (LY3009104) in Participants With Severe or Very Severe Alopecia Areata

Checkmark Efficacy and safety data from BRAVE-AA1 trial in adults with severe alopecia areata
Apr 2021 - Apr 2021: Efficacy and safety data from BRAVE-AA1 trial in adults with severe alopecia areata
Checkmark From BRAVE-AA1 trial for alopecia areata
Oct 2020 - Oct 2020: From BRAVE-AA1 trial for alopecia areata
Active, not recruiting
2/3
824
Japan, US, RoW
Baricitinib, LY3009104, Placebo
Eli Lilly and Company, Incyte Corporation
Alopecia Areata
02/21
01/25
NCT06073132: An International, Multicenter, Randomized, Double-Blind, Parallel Group, Vehicle-Controlled, Phase 2/3 Study With Open-Label Extension Evaluating the Efficacy and Safety of Diacerein 1% Ointment for the Treatment of Generalized Epidermolysis Bullosa Simplex (EBS)

Recruiting
2/3
80
Europe, US, RoW
AC-203, Vehicle
TWi Biotechnology, Inc.
Generalized Epidermolysis Bullosa Simplex
08/25
03/26
NCT06046729: A Study of Eltrekibart (LY3041658) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa

Recruiting
2
350
Europe, Canada, US, RoW
Eltrekibart, LY3041658, Placebo
Eli Lilly and Company
Hidradenitis Suppurativa
08/25
07/26
NCT03827798 / 2018-002757-30: Study of Efficacy and Safety of Investigational Treatments in Patients With Moderate to Severe Hidradenitis Suppurativa

Active, not recruiting
2
248
Europe, US, RoW
CFZ533, Placebo to CFZ533, LYS006, Placebo to LYS006, MAS825, Placebo to MAS825, LOU064 25mg, LOU064 100mg, Placebo to LOU064, VAY736, Placebo to VAY736
Novartis Pharmaceuticals
Hidradenitis Suppurativa
12/24
12/26
TARGET-DERM, NCT03661866: A Longitudinal Observational Study of Patients Undergoing Therapy for IMISC

Recruiting
N/A
15000
Europe, Canada, US
Target PharmaSolutions, Inc.
Atopic Dermatitis, Alopecia Areata, Hidradenitis Suppurativa, Vitiligo, Psoriasis, Chronic Spontaneous Urticaria
12/50
12/50
Tummala, Mohan
NCT05234177: Tempus CRC Surveillance Study: a CtDNA Biomarker Profiling Study of Patients with CRC Using NGS Assays

Recruiting
N/A
160
US
Observation
Tempus AI
Colorectal Cancer
02/25
02/27
NCT05236114: GEMINI-NSCLC: NSCLC Biomarker Study

Recruiting
N/A
1200
US
Observation
Tempus AI, AstraZeneca
Non-Small Cell Lung Cancer
06/29
06/29
Richardson, Irma M
NCT05582434: Experience With Topical Acne Treatment

Recruiting
1
72
US
Adapalene Gel, Differin, Adapalene Gel and the clindamycin phosphate/benzoyl peroxide gel, Differin and ONEXTON, adapalene, benzoyl peroxide gel, and clindamycin phosphate gel every day., Differin, Epsolay, Clindamycin
Wake Forest University Health Sciences, Bausch Health Americas, Inc.
Acne
05/25
11/25
NCT05570955: Deucravacitinib Adherence Study

Recruiting
N/A
40
US
Text reminder
Wake Forest University Health Sciences, Bristol-Myers Squibb
Psoriasis
07/25
12/25
TARGET-DERM, NCT03661866: A Longitudinal Observational Study of Patients Undergoing Therapy for IMISC

Recruiting
N/A
15000
Europe, Canada, US
Target PharmaSolutions, Inc.
Atopic Dermatitis, Alopecia Areata, Hidradenitis Suppurativa, Vitiligo, Psoriasis, Chronic Spontaneous Urticaria
12/50
12/50
Rowley, Courtney
ASCEND, NCT05295732: The Study: Evaluating TMB-001 in the Treatment of RXLI or ARCI Ichthyosis

Completed
3
209
Europe, Canada, US
TMB-001, Matching Vehicle
Timber Pharmaceuticals Inc., LEO Pharma
Ichthyosis
06/24
09/24
TARGET-DERM, NCT03661866: A Longitudinal Observational Study of Patients Undergoing Therapy for IMISC

Recruiting
N/A
15000
Europe, Canada, US
Target PharmaSolutions, Inc.
Atopic Dermatitis, Alopecia Areata, Hidradenitis Suppurativa, Vitiligo, Psoriasis, Chronic Spontaneous Urticaria
12/50
12/50
Hylton, Jennifer
NCT05234177: Tempus CRC Surveillance Study: a CtDNA Biomarker Profiling Study of Patients with CRC Using NGS Assays

Recruiting
N/A
160
US
Observation
Tempus AI
Colorectal Cancer
02/25
02/27
NCT05236114: GEMINI-NSCLC: NSCLC Biomarker Study

Recruiting
N/A
1200
US
Observation
Tempus AI, AstraZeneca
Non-Small Cell Lung Cancer
06/29
06/29
Wenzel, Abby
NIGHTINGALE, NCT06426628: Clinical Utility of Management of Patients With Pulmonary Nodules Using the Percepta Nasal Swab Classifier

Recruiting
N/A
2400
US
Veracyte, Inc.
Pulmonary Nodule, Solitary, Lung Cancer
12/24
03/27
TARGET, NCT04182815: Transbronchial Biopsy Assisted by Robot Guidance in the Evaluation of Tumors of the Lung

Completed
N/A
691
Canada, US, RoW
Robotic assisted bronchoscopy, Robotic assisted bronchoscopy with Monarch platform
Auris Health, Inc.
Pulmonary Nodule, Lung Cancer
12/23
12/23
Gross, Christopher
NCT01191151: Web Based Orthopaedic Sports Medicine Registry

Terminated
N/A
12500
Europe, Canada, US, RoW
Arthrex, Inc.
Degenerative and Traumatic Pathology of the Knee, Degenerative and Traumatic Pathology of the Shoulder and Elbow, Degenerative and Traumatic Pathology of the Foot and Ankle, Degenerative and Traumatic Pathology of the Hand and Wrist, Degenerative and Traumatic Pathology of the Hip
07/23
07/23
NCT04784156: Use of a Sustained Dynamic Compression Intramedullary Nail for Subtalar Arthrodesis

Not yet recruiting
N/A
60
US
Subtalar (Talocalcaneal) Arthrodesis, DynaNail Mini
MedShape, Inc, Medical University of South Carolina
Foot Arthritis
03/24
03/24
NCT04770870: Post Approval Study2: Hintermann Series H3 Total Ankle Replacement System

Recruiting
N/A
232
US
Hintermann Series H3 Total Ankle Replacement System
DT MedTech, LLC
Osteoarthritis Ankle, Post-Traumatic Osteoarthritis of Ankle, Osteoarthritis of Ankle Secondary to Inflammatory Arthritis (Disorder)
04/29
04/29
ITAR2, NCT04594993: INFINITY™ With ADAPTIS™ Technology Study

Active, not recruiting
N/A
200
US
INFINITY™ with ADAPTIS™ Technology Total Ankle System
Stryker Trauma and Extremities
Arthritis, Rheumatoid
11/33
11/35
Scott, Daniel
NCT01191151: Web Based Orthopaedic Sports Medicine Registry

Terminated
N/A
12500
Europe, Canada, US, RoW
Arthrex, Inc.
Degenerative and Traumatic Pathology of the Knee, Degenerative and Traumatic Pathology of the Shoulder and Elbow, Degenerative and Traumatic Pathology of the Foot and Ankle, Degenerative and Traumatic Pathology of the Hand and Wrist, Degenerative and Traumatic Pathology of the Hip
07/23
07/23
NCT04784156: Use of a Sustained Dynamic Compression Intramedullary Nail for Subtalar Arthrodesis

Not yet recruiting
N/A
60
US
Subtalar (Talocalcaneal) Arthrodesis, DynaNail Mini
MedShape, Inc, Medical University of South Carolina
Foot Arthritis
03/24
03/24
NCT05364606: Patient Specific Talus Spacer Post Approval Study

Recruiting
N/A
50
US
Patient Specific Talus Spacer
Paragon 28
Avascular Necrosis of the Talus
08/29
11/29
Cypcar, David
NCT06372496: Pragmatic Open - Label Randomized Clinical Trial of FF/UMEC/VI vs Non-ellipta Usual Care ICS-LABA for Adult Participants With Uncontrolled Asthma

Recruiting
4
1136
Canada, Japan, US, RoW
Fluticasone furoate/umeclidinium bromide/vilanterol trifenatate, Inhaled corticosteroids/long-acting beta-2 agonists
GlaxoSmithKline
Asthma
03/26
03/26
PREPARED-1, NCT06339008: A Study of Lebrikizumab in Adult Participants With Perennial Allergic Rhinitis

Recruiting
3
450
Europe, US, RoW
LY3650150, Placebo, Standard therapy for INCS
Eli Lilly and Company
Perennial Allergic Rhinitis (PAR)
10/25
02/27
NCT06261957: A Study to Assess and Compare Safety and Tolerability of 3 Months Treatment With Salbutamol Administered Via MDI Containing Propellant HFA-152a or HFA-134a in Participants ≥ 18 Years of Age With Asthma

Recruiting
3
412
Europe, Canada, US, RoW
Salbutamol HFA-134a, Salbutamol HFA-152a
GlaxoSmithKline
Asthma
04/25
04/25
NIMBLE, NCT04718389 / 2020-003612-28: A Study of GSK3511294 (Depemokimab) Compared With Mepolizumab or Benralizumab in Participants With Severe Asthma With an Eosinophilic Phenotype

Hourglass Feb 2024 - Jun 2024 : Acceptance of regulatory submission in China for CRSwNP
Active, not recruiting
3
1667
Europe, Canada, Japan, US, RoW
GSK3511294 (Depemokimab), Mepolizumab, Benralizumab, Placebo, Standard of care (SoC), Pre-filled Syringes (PFS)
GlaxoSmithKline, Iqvia Pty Ltd
Asthma
10/25
10/25
CALM-CSU, NCT06077773: Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of EP262 in Subjects With Chronic Spontaneous Urticaria

Recruiting
2
154
Europe, Canada, US
Oral EP262, Placebo
Escient Pharmaceuticals, Inc
Chronic Spontaneous Urticaria
06/25
07/25
TARGET-DERM, NCT03661866: A Longitudinal Observational Study of Patients Undergoing Therapy for IMISC

Recruiting
N/A
15000
Europe, Canada, US
Target PharmaSolutions, Inc.
Atopic Dermatitis, Alopecia Areata, Hidradenitis Suppurativa, Vitiligo, Psoriasis, Chronic Spontaneous Urticaria
12/50
12/50
Hoch, Caroline
NCT04784156: Use of a Sustained Dynamic Compression Intramedullary Nail for Subtalar Arthrodesis

Not yet recruiting
N/A
60
US
Subtalar (Talocalcaneal) Arthrodesis, DynaNail Mini
MedShape, Inc, Medical University of South Carolina
Foot Arthritis
03/24
03/24
Padilla, Felicia
NCT05654922: Study to Evaluate ARINA-1 in the Prevention of Bronchiolitis Obliterans Progression in Participants With Bilateral Lung Transplant

Recruiting
3
100
US
ARINA-1, Standard of care only
Renovion, Inc.
Pre-Bronchiolitis Obliterans Syndrome
01/25
06/25
NCT05667662 / 2022-002289-33: Study to Evaluate Itraconazole Administered as Inhaled Dry Powder in Adults With Asthma and ABPA

Terminated
2
8
Europe, US, RoW
Itraconazole Powder, PUR1900, Placebo
Pulmatrix Inc., Pulmatrix, Inc.
ABPA
02/24
02/24
NCT05671835: Study of TTI-101 in Participants With Idiopathic Pulmonary Fibrosis

Recruiting
2
75
US
TTI-101, Placebo
Tvardi Therapeutics, Incorporated
Idiopathic Pulmonary Fibrosis
03/25
07/25
ALTA TIPS, NCT03973372: A 5-year Longitudinal Observational Study of Patients Undergoing TIPS Placement

Active, not recruiting
N/A
852
US
University of Texas Southwestern Medical Center, University of California, San Francisco, Scripps Health, University of Wisconsin, Madison, University of Florida, University of Arizona, Stanford University, Columbia University, Weill Medical College of Cornell University, Baylor Scott and White Health, Mayo Clinic, University of Chicago, Digestive Health Foundation, W.L.Gore & Associates, University of Minnesota, Northwestern University
Cirrhosis, Liver, Transjugular Intrahepatic Portosystemic Shunt (TIPS)
12/25
12/27
NCT05837663: Trifecta-Lung cfDNA-MMDx Study

Recruiting
N/A
600
Europe, Canada, US, RoW
University of Alberta, Natera, Inc., One Lambda
Lung Transplantation
11/26
12/27
NCT03639025: OCS™ Lung TOP Registry For Donor Lungs for Transplantation

Active, not recruiting
N/A
458
US
OCS Lung System
TransMedics
Lung Transplantation
11/25
11/29
Schlichting, David
TARGET-DERM, NCT03661866: A Longitudinal Observational Study of Patients Undergoing Therapy for IMISC

Recruiting
N/A
15000
Europe, Canada, US
Target PharmaSolutions, Inc.
Atopic Dermatitis, Alopecia Areata, Hidradenitis Suppurativa, Vitiligo, Psoriasis, Chronic Spontaneous Urticaria
12/50
12/50
Hernandez, Daisy
TARGET-DERM, NCT03661866: A Longitudinal Observational Study of Patients Undergoing Therapy for IMISC

Recruiting
N/A
15000
Europe, Canada, US
Target PharmaSolutions, Inc.
Atopic Dermatitis, Alopecia Areata, Hidradenitis Suppurativa, Vitiligo, Psoriasis, Chronic Spontaneous Urticaria
12/50
12/50
A, Shahrukh
NCT05671835: Study of TTI-101 in Participants With Idiopathic Pulmonary Fibrosis

Recruiting
2
75
US
TTI-101, Placebo
Tvardi Therapeutics, Incorporated
Idiopathic Pulmonary Fibrosis
03/25
07/25
Empey, Robyn
NCT05671835: Study of TTI-101 in Participants With Idiopathic Pulmonary Fibrosis

Recruiting
2
75
US
TTI-101, Placebo
Tvardi Therapeutics, Incorporated
Idiopathic Pulmonary Fibrosis
03/25
07/25
Shenoy, Sangeeta
NCT05671835: Study of TTI-101 in Participants With Idiopathic Pulmonary Fibrosis

Recruiting
2
75
US
TTI-101, Placebo
Tvardi Therapeutics, Incorporated
Idiopathic Pulmonary Fibrosis
03/25
07/25
Handy, Danielle
NCT06126003: Gut and Tumor Microbiome in Patients With Early Stage (II-III), Locally Advanced or Advanced ER-positive and HER2-negative Breast Cancer.

Terminated
N/A
2
US
Observation
BioCorteX Inc, Tempus AI
Breast Cancer
07/24
07/24
NCT05236114: GEMINI-NSCLC: NSCLC Biomarker Study

Recruiting
N/A
1200
US
Observation
Tempus AI, AstraZeneca
Non-Small Cell Lung Cancer
06/29
06/29

Download Options